Spago Nanomedical AB implement a directed share issue of 8.7 MSEK to HealthInvest Small & MicroCap Fund. A total of 860 000 shares are issued for a subscription price of 10.15 SEK per share.
The subscription price correspond to the volume weighted average share price for the two weeks preceding the board of Spago Nanomedical´s decision on the share issue.
The board of Spago Nanomedical has resolved on the share issue based on the mandate given by the Annual General Meeting on 17 May 2017. The reason for the deviation from the precedency of the shareholders is to broaden the ownership basis. The board´s assessment is that the issue is done at a price that is coherent with the market and that it adds an owner with solid experience of life science which will benefit the company and its shareholders.
The payment from the share issue will facilitate the development of the company´s projects, SpagoPix and Tumorad®.
HealthInvest Small & MicroCap Fund is a specialist fund investing globally in companies within the area of health and wellbeing, emphasising on small companies. The fund has a strong track record of revenues and is rated at five stars by Morningstar. HealthInvest Small & MicroCap Fund fis managed by HealthInvest Partners AB, a Swedish company founded in 2006 by Carl Bennet and Anders Hallberg.
The share issue results in dilution by approximately 6 percent and the number of shares is increased to 15 196 803.
For further information, please contact Mats Hansen, CEO Spago Nanomedical AB, +46 767 76 42 94, firstname.lastname@example.org.